FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083786790> ?p ?o ?g. }

• W2083786790 endingPage "3025" @default.
• W2083786790 startingPage "3016" @default.
• W2083786790 abstract "The Her2/neu (c-erbB-2) oncogene encodes a 185-kDa protein tyrosine kinase which is overexpressed in 20% of breast adenocarcinomas and is recognized by a humanized anti-Her2/neu monoclonal antibody (mAb) (rhu4D5 or Herceptin). Natural killer (NK) cells are capable of mediating antibody-dependent cell cytotoxicity (ADCC) against antibody-coated targets via their expression of a low-affinity receptor for IgG (FcgammaRIII or CD16). NK cells can be expanded in cancer patients via the administration of low-dose interleukin-2 (IL-2) and become potent cytotoxic effectors following exposure to high doses of IL-2. We tested IL-2-activated NK cells against Her2/neu+ (MCF-7Her2/neu) and Her2/neu- (MDA-468) breast cancer cell lines in a 4-h 51Cr-release cytotoxicity assay in the presence or absence of rhu4D5 mAb (effector : target ratio = 10 : 1). Specific lysis of rhu4D5-coated MCF-7Her2/neu and MDA-468 target cells by IL-2-activated NK cells was 35% and 3%, respectively (p < 0.05). Lysis was less than 5% when targets were treated with either the non-humanized mu4D5 mAb or control huIgG. Lysis of rhu4D5-coated MCF-7Her2/neu cells was inhibited by 80 % when NK cells were pre-treated with an anti-Fc receptor antibody prior to use in the cytotoxicity assay. Enhanced ADCC of MCF-7Her2/neu target cells was seen when the effector cells consisted of mononuclear cells obtained from a patient demonstrating significant expansion of NK cells secondary to therapy with low-dose IL-2. Serum from patients receiving infusions of rhu4D5 mAb could substitute for exogenous antibody in the ADCC assay. NK cells activated by rhu4D5-coated tumor cells in the presence of IL-2 also produced large amounts of IFN-gamma with concomitant up-regulation of cell-surface activation markers CD25 and CD69. These results lend support to the concurrent use of rhu4D5 mAb and IL-2 therapy in patients with cancers that express the Her2/neu oncogene." @default.
• W2083786790 created "2016-06-24" @default.
• W2083786790 creator A5008768048 @default.
• W2083786790 creator A5011012477 @default.
• W2083786790 creator A5027100101 @default.
• W2083786790 creator A5049192022 @default.
• W2083786790 creator A5053128814 @default.
• W2083786790 creator A5059373658 @default.
• W2083786790 creator A5060897770 @default.
• W2083786790 creator A5066431842 @default.
• W2083786790 date "2001-10-01" @default.
• W2083786790 modified "2023-10-15" @default.
• W2083786790 title "Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells" @default.
• W2083786790 cites W1499509353 @default.
• W2083786790 cites W1557111800 @default.
• W2083786790 cites W1656008630 @default.
• W2083786790 cites W1965219484 @default.
• W2083786790 cites W1966887368 @default.
• W2083786790 cites W1973284702 @default.
• W2083786790 cites W1977299595 @default.
• W2083786790 cites W1990135376 @default.
• W2083786790 cites W1993555313 @default.
• W2083786790 cites W1998870570 @default.
• W2083786790 cites W2006073656 @default.
• W2083786790 cites W2006174096 @default.
• W2083786790 cites W2011470870 @default.
• W2083786790 cites W2028345258 @default.
• W2083786790 cites W2028743952 @default.
• W2083786790 cites W2039609199 @default.
• W2083786790 cites W2071763005 @default.
• W2083786790 cites W2077252019 @default.
• W2083786790 cites W2082117763 @default.
• W2083786790 cites W2090639012 @default.
• W2083786790 cites W2095156669 @default.
• W2083786790 cites W2095636772 @default.
• W2083786790 cites W2103827956 @default.
• W2083786790 cites W2104066024 @default.
• W2083786790 cites W2112475887 @default.
• W2083786790 cites W2128402413 @default.
• W2083786790 cites W2132363654 @default.
• W2083786790 cites W2149235787 @default.
• W2083786790 cites W2161428561 @default.
• W2083786790 cites W2314331148 @default.
• W2083786790 cites W4230564818 @default.
• W2083786790 doi "https://doi.org/10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j" @default.
• W2083786790 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11592078" @default.
• W2083786790 hasPublicationYear "2001" @default.
• W2083786790 type Work @default.
• W2083786790 sameAs 2083786790 @default.
• W2083786790 citedByCount "141" @default.
• W2083786790 countsByYear W20837867902012 @default.
• W2083786790 countsByYear W20837867902013 @default.
• W2083786790 countsByYear W20837867902014 @default.
• W2083786790 countsByYear W20837867902015 @default.
• W2083786790 countsByYear W20837867902016 @default.
• W2083786790 countsByYear W20837867902017 @default.
• W2083786790 countsByYear W20837867902018 @default.
• W2083786790 countsByYear W20837867902019 @default.
• W2083786790 countsByYear W20837867902020 @default.
• W2083786790 countsByYear W20837867902021 @default.
• W2083786790 countsByYear W20837867902022 @default.
• W2083786790 countsByYear W20837867902023 @default.
• W2083786790 crossrefType "journal-article" @default.
• W2083786790 hasAuthorship W2083786790A5008768048 @default.
• W2083786790 hasAuthorship W2083786790A5011012477 @default.
• W2083786790 hasAuthorship W2083786790A5027100101 @default.
• W2083786790 hasAuthorship W2083786790A5049192022 @default.
• W2083786790 hasAuthorship W2083786790A5053128814 @default.
• W2083786790 hasAuthorship W2083786790A5059373658 @default.
• W2083786790 hasAuthorship W2083786790A5060897770 @default.
• W2083786790 hasAuthorship W2083786790A5066431842 @default.
• W2083786790 hasBestOaLocation W20837867901 @default.
• W2083786790 hasConcept C109316439 @default.
• W2083786790 hasConcept C114684123 @default.
• W2083786790 hasConcept C121608353 @default.
• W2083786790 hasConcept C129374314 @default.
• W2083786790 hasConcept C147483822 @default.
• W2083786790 hasConcept C149532602 @default.
• W2083786790 hasConcept C153911025 @default.
• W2083786790 hasConcept C154317977 @default.
• W2083786790 hasConcept C159654299 @default.
• W2083786790 hasConcept C167672396 @default.
• W2083786790 hasConcept C202751555 @default.
• W2083786790 hasConcept C203014093 @default.
• W2083786790 hasConcept C2776090121 @default.
• W2083786790 hasConcept C2776872082 @default.
• W2083786790 hasConcept C2778102761 @default.
• W2083786790 hasConcept C2779786085 @default.
• W2083786790 hasConcept C2781462264 @default.
• W2083786790 hasConcept C28651165 @default.
• W2083786790 hasConcept C40677261 @default.
• W2083786790 hasConcept C502942594 @default.
• W2083786790 hasConcept C530470458 @default.
• W2083786790 hasConcept C542903549 @default.
• W2083786790 hasConcept C54355233 @default.
• W2083786790 hasConcept C55493867 @default.
• W2083786790 hasConcept C86803240 @default.
• W2083786790 hasConcept C8891405 @default.

• next